The rising interest in GLP-1 agonists for metabolic conditions has generated a debate about delivery routes : skin-applied devices versus capsules. Traditionally , GLP-1 therapies were solely available in https://emilieqjmq117151.bluxeblog.com/73351329/glp-1-transdermal-delivery-systems-vs-tablets-what-right-for-individuals